DRUG
CT-868
CT-868
A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes
Status
Completed
Phase
Phase 1
Enrollment
32
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
This study will be conducted primarily to evaluate the effects of CT-868 on glucose homeostasis in participants with Type 1 Diabetes Mellitus.
Interventions
Treatment arms and agents.
DRUG
Placebo
Placebo as SC Injection
DRUG
Victoza
Victoza as active comparator as SC Injection
Timeline
From registration to results.
First posted
Apr 3, 2023
Study start
Mar 21, 2023
Primary completion
Mar 6, 2024
Study completion
Apr 6, 2024
Results posted
Not reported
Registry updated
Dec 27, 2024
Outcomes
What the study measures.
Primary outcomes
To assess area under the curve (AUC) in glucose metabolism during MMTT
Time frame · Baseline up to 4 days
Secondary outcomes
To assess changes in continuous glucose monitoring (CGM) measures
Time frame · Baseline up to 4 days
Area under the acetaminophen concentration-time (AUC)
Time frame · 0 - 300 minutes
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 65 Years
- Sex
- ALL
- Healthy volunteers
- Yes
Inclusion Criteria: * Female or male adults with Type 1 diabetes * Ages 18-65 years * Type 1 DM for at least 3 years * Using an insulin pump or multiple daily injections (MDI) for at least 3 months * BMI 25.0 - 35.0 Exclusion Criteria: * Significant medical history * Uncontrolled diabetes * History of surgical treatment for weight loss * History of malignancy
Study locations
1 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Carmot Clinical Research Unit 101
Chula Vista, California, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Liraglutide.
NCT IDStudyPhase / statusEnrollmentUpdated
Fibrosis Lessens After Metabolic Surgery
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis
4Moving Biotech · Knee Osteoarthritis · Synovitis of Knee
Phase 2
Active, not recruiting
129
2026-07
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Ohio State University · Obesity & Overweight · Diabetes (DM)
Not applicable
Recruiting
300
2026-07
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Type 2 Diabetes Mellitus · Mild Cognitive Impairment
Not applicable
Completed
396
2026-07
Phase 1
Recruiting
71
2026-07
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
Novo Nordisk · Obesity
Phase 3
Active, not recruiting
78
2026-07
GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation
West China Hospital · Alzheimer Disease · Diabetes Mellitus Type 2
Not applicable
Completed
213,891
2026-07
Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes
Indiana University · Obesity
Not applicable
Enrolling by invitation
125,000
2026-06
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.